KHALIULLIN, F.A.,
KLEN, E.E.,
PAVLOV, V.N.,
SAMORODOV, A.V.,
SHEPILOVA, S.O.,
MAKAROVA, N.N.,
NURLANOVA, S.N.,
ABZALILOV, T.N. (2022) 5-Alkoxy- and
5-amino-substituted 3-bromo-4-nitro-1-(thietan-3-yl)-1H-pyrazoles were synthesized
5-Oxymethyluracil Stimulate Neoangiogenesis in Postinfarction Cardiosclerosis Model in Rabbits
of neuropharmacological interaction.
Materials and methods: To study the mechanism of action of N-199/1, its effect on
5Khazhiev, S.Y.,
Khusainov, M.A.,
Khalikov, R.A.,
Kataev, V.A.,
Tyumkina, T.V.,
Mescheryakova, E.S.,
Khalilov, L.M.,
Kuznetsov, V.V. (2022) According to the NMR 1Н, 13С and X-ray analysis data molecules of
5,5-bis(bromomethyl)-2
Tyurin, Anton,
Merkuryeva, Elena,
Zaripova, Aliya,
Markova, Tatyana,
Nagornova, Tatyana,
Dantsev, Ilya,
Nadyrshina, Dina,
Zakharova, Ekaterina,
Khusainova, Rita (2022) shown that a mutation (c.-14C>T) in the IFITM
5 gene is responsible for autosomal dominant OI type V
-administered with
5HT1A- (WAY100635, 0.1 mg/kg),
5HT2A/2C- (ketanserin,
5 mg/kg),
5HT3- (ondansetron, 1 mg
Dobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. (2022) diseases with a high rate of mortality in patients with SSDs. Neuropeptide Y receptor Y
5 (NPY
5R) is known